Hexarelin

What it is

Hexarelin is a synthetic growth hormone-releasing peptide in the same broad research family as GHRP-2, GHRP-6, and ipamorelin^{[5 ,14 ]}. It was developed during the era of growth hormone secretagogue research, when investigators were looking for orally or parenterally active molecules that could stimulate endogenous growth hormone release without directly administering recombinant growth hormone^{[5 ]}.

At the receptor level, hexarelin is a peptidyl agonist of the growth hormone secretagogue receptor, also known as the ghrelin receptor or GHS-R1a^{[5 ,7 ]}. In human studies, acute hexarelin administration stimulated growth hormone and also affected other pituitary-adrenal hormones, including ACTH, cortisol, and prolactin^{[7 –9 ]}. This broader endocrine activity is clinically relevant because public discussion often reduces hexarelin to “GH release,” while the published human physiology literature shows a wider hormone-response profile.

Hexarelin has also attracted cardiovascular research interest. Small human studies examined acute effects in severe left ventricular dysfunction and coronary artery disease during bypass surgery^{[10 –11 ]}. Preclinical studies and reviews describe possible GH-independent actions, including CD36-related effects on macrophage cholesterol handling and experimental atherosclerosis models^{[12 –13 ]}. These findings are hypothesis-generating and do not establish an approved cardiovascular indication.

In research settings, hexarelin has been administered by injection or nasal routes depending on the study^{[8 ,14 ]}. Grey-market products may be labeled as hexarelin acetate or examorelin, but such labeling does not establish identity, purity, legality, or clinical appropriateness. This page is descriptive and does not provide dosing instructions.

Regulatory status

Hexarelin is not FDA-approved for growth hormone deficiency, sarcopenia, bodybuilding, anti-aging, heart disease, sleep, or any other indication in the United States. No FDA-approved prescribing information for hexarelin was identified in the FDA sources reviewed for this draft.

503A and 503B compounding

For 503A pharmacy compounding, FDA states that bulk drug substances must meet one of three pathways: an applicable USP/NF monograph, status as a component of an FDA-approved drug product when no monograph exists, or inclusion on FDA’s 503A bulks list^{[1 ]}. Hexarelin was not listed in the April 22, 2026 503A category document reviewed for this draft^{[2 ]}. Absence from Category 1 means this draft did not identify a current FDA interim-policy pathway for routine 503A compounding^{[1 –2 ]}.

For 503B outsourcing facilities, FDA states that a bulk drug substance must appear on the 503B bulks list or the compounded drug must appear on FDA’s drug shortage list at the time of compounding, distribution, and dispensing^{[3 ]}. No 503B bulks-list or shortage-list pathway for hexarelin was identified during this review^{[3 ]}.

Controlled-substance and international status

Hexarelin is not listed in the federal controlled-substance schedules in 21 CFR Part 1308 as reviewed on May 7, 2026^{[4 ]}. That does not make it an FDA-approved drug and does not resolve compounding, importation, prescription, anti-doping, or professional-practice issues.

Internationally, hexarelin has appeared in scientific and anti-doping contexts under the name examorelin, but no major US-approved clinical product was identified for this draft. Regulatory status should be rechecked against FDA databases before publication.

Research summary

The human research base for hexarelin is mostly endocrine physiology, not therapeutic outcome trials. Smith’s review of growth hormone secretagogue development describes the broader drug-development context for compounds designed to stimulate endogenous GH secretion^{[5 ]}. Deghenghi later characterized hexarelin as a “multi-receptor peptide,” reflecting the observation that its pharmacology was not limited to a single simple GH-release mechanism^{[6 ]}.

Endocrine physiology

In healthy volunteers, acute hexarelin stimulated GH secretion and interacted with ghrelin and GHRH physiology^{[7 ]}. Maccario and colleagues studied two or three daily subcutaneous injections of hexarelin and reported effects on 24-hour GH, prolactin, ACTH, and cortisol secretion^{[8 ]}. Frieboes and colleagues found that hexarelin decreased slow-wave sleep while stimulating GH, ACTH, cortisol, and prolactin during sleep in healthy volunteers^{[9 ]}. These data support biologic activity but do not establish therapeutic benefit for wellness, performance, sleep improvement, or aging.

Cardiovascular studies

Small cardiovascular studies are frequently cited but should be interpreted cautiously. Imazio and colleagues reported GH-independent cardiotropic activity in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy^{[10 ]}. Broglio and colleagues studied acute administration during bypass surgery in patients with coronary artery disease^{[11 ]}. These were small, specialized studies focused on acute physiologic outcomes rather than long-term clinical endpoints such as mortality, hospitalization, exercise capacity, or quality of life.

Preclinical cardiovascular literature provides mechanistic hypotheses. Avallone and colleagues reported that a growth hormone-releasing peptide binding CD36 and the ghrelin receptor influenced macrophage sterol transporters and cholesterol efflux through a PPAR-gamma-dependent pathway^{[12 ]}. Pang and colleagues reported that hexarelin suppressed diet- and vitamin D3-induced atherosclerosis in rats^{[13 ]}. These findings do not establish human cardiovascular efficacy.

Anti-doping analytical work

Anti-doping and analytical studies show that hexarelin is part of the broader family of detectable growth hormone-releasing peptides. Ferro and colleagues evaluated structure-activity relationships for peptidic growth hormone secretagogues^{[14 ]}. Semenistaya and colleagues studied urinary metabolites after nasal administration of GHRP-1, GHRP-2, GHRP-6, hexarelin, and ipamorelin^{[15 ]}. These papers are useful for identification and misuse contexts, not for clinical benefit claims.

Where the evidence ends

Overall, evidence for hexarelin consists of small human endocrine studies, small acute cardiovascular studies, and animal or mechanistic research. No large randomized controlled trial supporting routine clinical use for body composition, anti-aging, cardiovascular disease, immune function, or sleep was identified as of May 7, 2026.

The clinical evidence should also be separated by research question. For the narrow question “does hexarelin stimulate human pituitary hormone release,” the answer is supported by controlled physiology studies^{[7 –9 ]}. For the broader question “does hexarelin improve health outcomes,” the evidence is much weaker. The cardiovascular studies were small and acute; the endocrine studies measured hormones rather than patient-centered outcomes; and anti-doping analytical papers establish detectability rather than therapeutic value^{[10 –15 ]}.

This distinction matters because growth hormone secretagogues are often promoted using hormone-response data as if those responses automatically imply improved strength, body composition, recovery, or longevity. Published hexarelin studies do not establish those endpoints. They show that hexarelin is biologically active and can perturb several hormone systems, which is a reason for caution as well as scientific interest^{[7 –9 ]}.

Healthy-volunteer endocrine studies, intraoperative coronary artery disease studies, and heart-failure physiology studies do not answer the same questions that consumers usually have about repeated use in otherwise healthy adults^{[7 –11 ]}. The available studies also do not define a long-term monitoring strategy, discontinuation criteria, or risk stratification approach. That leaves a substantial gap between “has measurable endocrine activity” and “has a defensible clinical role.”

Public discourse

No qualifying public-discourse entries were identified for this page. The search found marketing pages, clinic pages, and anonymous forum discussion, but no accessible named-source podcast, article, or transcript with a verifiable quote meeting this site’s citation standard.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

Published human studies show that hexarelin can affect multiple hormone axes. In healthy volunteers, hexarelin stimulated GH, ACTH, cortisol, and prolactin, and altered slow-wave sleep in one study^{[8 –9 ]}. Theoretical concerns therefore include endocrine effects beyond GH release, including effects on adrenal-axis hormones and prolactin.

Mechanism-based concerns

Because hexarelin stimulates the GH/IGF-1 axis, theoretical concerns overlap with other GH secretagogues: edema, carpal-tunnel-like symptoms, glucose intolerance, insulin resistance, headache, appetite changes, and effects in people with active malignancy or conditions sensitive to growth-factor signaling. These are mechanistic concerns rather than hexarelin-specific FDA-labeled adverse reactions, because hexarelin has no FDA-approved label.

Long-term safety unknown

Long-term safety data are limited. The available human studies were small and often short-term, and the cardiovascular studies were not designed to characterize chronic safety in general users^{[8 –11 ]}. No FDA-reviewed contraindication list, pregnancy safety data, drug-interaction framework, or postmarketing surveillance system exists for hexarelin as an approved US drug.

Cardiovascular findings should not be generalized into clinical recommendations. Small studies in heart failure or coronary artery disease investigated controlled acute responses in selected patients^{[10 –11 ]}. They do not establish safety for people using hexarelin for bodybuilding, recovery, or age-related wellness, and they do not answer whether repeated use could worsen fluid retention, blood pressure, glucose tolerance, arrhythmia risk, or other clinically relevant outcomes.

Compounded product risks

Compounded or grey-market products add additional risks: uncertain identity, purity, sterility, peptide aggregation, and dose accuracy. These risks are particularly important for injectable peptides and should not be inferred away from the existence of small research studies.

Available through

Hexarelin is not currently available through FDA-compliant prescription or compounding channels in the United States as of 2026-05-07^{[1 –3 ]}. It is not FDA-approved, was not identified on the 503A bulks list or 503A Category 1 interim-policy list, and was not identified on the 503B bulks list or shortage-list pathway^{[1 –3 ]}.

ProPeptideGuide does not link to or endorse grey-market vendors, “research chemical” sellers, online peptide shops, or clinics advertising hexarelin for body composition, recovery, anti-aging, or athletic performance.